Press Releases

First Previous Next End

February 24, 2015

Provectus Biopharmaceuticals Will Hold Its 2014 Year-End Quarterly Business Update Conference Call at 4 PM Eastern, Thursday, March 12, 2015

Provectus announced today that it will hold its year-end quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, March 12, 2015.

February 18, 2015

Provectus Biopharmaceuticals Will Present at 8th Annual European Life Science CEO Forum & Exhibition

Provectus announced today that it will present at the 8th Annual European Life Science CEO Forum & Exhibition. Peter Culpepper, CFO and COO, will present on March 3, 2015, at 3:15 pm local time.

February 10, 2015

Provectus Biopharmaceuticals Will Present at 17th Annual BIO CEO And Investor Conference Tuesday, February 10, 2015

Provectus announced today that it will present at the 17th Annual BIO CEO and Investor Conference on Tuesday, February 10,2015.

February 9, 2015

Provectus Biopharmaceuticals Met with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study

Provectus announced today that it has held a Type C meeting with the U.S. Food and Drug Administration to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma.

February 6, 2015

Provectus Biopharmaceutical's PV-10 Featured in Article by Sanjiv Agarwala in Current Opinion in Oncology

Provectus announced today that an article, entitled "Intralesional therapy for advanced melanoma: promise and limitation," authored by Sanjiv S. Agarwala, MD, has been published in the March issue of Current Opinion in Oncology, now available online.

January 29, 2015

Provectus Biopharmaceuticals Begins Recruitment for Phase 2 Mechanism of Action Clinical Trial Of PH-10 For Psoriasis

Provectus announced today that it has opened recruitment for its phase 2 mechanism of action trial of PH-10 for the treatment of mild to moderate psoriasis.

January 26, 2015

Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Office

Provectus announced today that it has received notification of allowance from the Chinese Patent Office for its patent application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the Company's lead oncology drug candidate.

December 23, 2014

Provectus Biopharmaceuticals' Protocol for Phase 2 Study of Mechanism of Action of PH-10 on Immunologic Markers of Psoriasis Now Available Online

Provectus announced today that the protocol for its phase 2 study of the mechanism of action of PH-10 in psoriasis is now available on ClinicalTrials.gov, Identifier NCT02322086:

December 22, 2014

Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed of Enrollment

Provectus announced today that it will be meeting with the U.S. Food and Drug Administration (the "FDA") to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma. No date for this meeting has been agreed upon as yet.

December 17, 2014

Provectus Biopharmaceuticals To Sponsor American Association of Physicians of Indian Origin

Provectus announced today that it has agreed to sponsor the activities of the American Association of Physicians of Indian Origin (AAPI). In addition, Provectus will participate at AAPI's 2015 Global Healthcare Summit in Mumbai, India, running from January 2-4, 2015, as well as at the Annual AAPI Conference in Orlando, Florida, running from June 17-21, 2015.

November 14, 2014

Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd

Provectus announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term.

November 13, 2014

Provectus Biopharmaceuticals' Protocol for Phase 3 Study Of PV-10 As Treatment for Melanoma Now Available Online

Provectus announced today that the protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available on: http://clinicaltrials.gov/ct2/show/study/NCT02288897?term=provectus&rank=6.

November 10, 2014

Provectus Biopharmaceuticals PV-10 Data Presented at SITC 29TH Annual Meeting

Provectus announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of cancer was featured in a poster presentation at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting on Saturday, November 8, 2014.

November 6, 2014

Provectus Biopharmaceuticals, Inc. Reports Third Quarter Results

Provectus today announced financial results for the third quarter of 2014.

November 6, 2014

Provectus Biopharmaceuticals Submits PV-10 Phase 3 Melanoma Protocol to FDA

Provectus announced today that it has submitted its phase 3 protocol for evaluation of PV-10 for treatment of locally advanced cutaneous melanoma to the FDA. The FDA is expected to review the submission and comment on the proposed study population, clinical endpoints, and statistical analyses within 30 to 45 days. Provectus believes details of the protocol will be available publicly on www.clinicaltrials.gov within the next few days.

November 6, 2014

Provectus Biopharmaceuticals Announces Abstract Available on Intralesional PV-10 and Co-inhibitory Blockade Data for SITC 29th Annual Meeting

Provectus announced today that the abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma," to be presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting is now available at http://www.immunotherapyofcancer.org/content/2/S3/P120.

November 6, 2014

Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call Today at 4 PM Eastern Standard Time

Provectus will host its quarterly conference call today, Thursday, November 6, 2014 at 4:00 PM EST.

October 31, 2014

Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call on Thursday, November 6, 2014

Provectus will host a quarterly conference call to update the market in general and shareholders in particular about developments at the Company. The call is scheduled for Thursday, November 6, 2014 at 4:00 PM EST.

October 28, 2014

Provectus' Intralesional PV-10 Clinical Data Published in the Annals of Surgical Oncology

Provectus announced today that data on its investigational new drug PV-10, obtained in clinical trial PV-10-MM-02 ( ClinicalTrials.gov Identifier NCT00521053), has been published by the Annals of Surgical Oncology (ASO).

October 16, 2014

Provectus' Intralesional PV-10 Clinical Data to Be Presented to the 2014 International Congress of the Society for Melanoma Research

Provectus announced today that Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University will present data on its investigational new drug PV-10 for the treatment of melanoma at the 11th International Congress of the Society for Melanoma Research in Zurich, Switzerland.

First Previous Next End